Cellestia presented promising clinical data of its lead compound CB-103 at ESMO 2020

Cellestia Biotech AG presented the first clinical data of its lead compound CB-103 at the virtual congress of the European Society for Medical Oncology (ESMO).

To read Cellestia’s press release click here.

Esmo 2020 Cellestia Poster

 

No next news